April 21, 2022

Late stage failures of monoclonal antibodies

Despite the significant developments that have happened in clinical trial design and the considerable experience that the biopharma industry has gained in the past three decades, therapeutic products continue to fail in late stage clinical trials. In this article, the authors showcase some of the monoclonal antibody (mAb) candidates that reached Phase III clinical trials but were discontinued at later stages.


Tags: , biotherapeutics, Mab, Monoclonal antibodies